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ABSTRACT
Chronic hepatitis B (CHB) is increasingly recognized as a public health problem
in Taiwan. After affected patients are diagnosed with contaminant liver cirrhosis
(LC), adverse clinical outcomes, especially death, are common. This study aimed
to investigate the effect of Chinese herbal medicine (CHM), an essential branch of
Traditional Chinese medicine (TCM), on the mortality risk among CHB patients with
contaminant LC. This longitudinal cohort study used the Taiwanese National Health
Insurance Research Database to identify 1522 patients 20–70 years of age with
newly diagnosed CHB with LC during 1998–2007. Among them, 508 (33.37%) had
received CHM products after the onset of CHB (CHM users), and the remaining 1014
patients (66.63%) were designated as a control group (non-CHM users). All enrollees
were followed until the end of 2012 to determine deaths during the study period. We
applied the Cox proportional hazards regression model to compute the hazard ratio
for the association of CHM use and the subsequent risk of death. During the follow-up
period, 156 CHM users and 493 non-CHM users died. After controlling for potential
confounders, CHM users were found to have a significantly reduced risk of death
compared with non-CHM users by 56%, and the effect was predominantly observed
among those treated with CHM for > 180 days. CHM therapy lowered the risk of death
among CHB patients with contaminant LC, which supported CHM might provide further
treatment options for those with chronic liver diseases.
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INTRODUCTION

shows the basic characteristics of the 2 groups. Compared
with non-CHM users, those who received CHM services
were more likely to be female and younger (< 50 years),
and to have a lower score of Charlson Comorbidity Index
(CCI) (all P < 0.01) (Table 1).
Among all eligible subjects, 649 deaths occurred,
including 493 non-CHM users and 156 CHM users, during
the follow-up periods of 3997.98 and 3644.58 person–
years (PY), respectively. The mortality rate was lower
in CHM users than in non-CHM users (42.80 vs 123.31,
respectively, per 1000 PY), with an adjusted hazard ratio
[3] of 0.44 (95% confidence interval [CI]: 0.36–0.52)
(Table 2). Of note, patients who used CHM treatments
for > 180 days had a 67% decreased risk of death (95%
CI: 0.25–0.42). Based on the Kaplan–Meier survival
curve and log-rank test results, a statistically significant
difference regarding the survival rate was observed across
the 3 groups during the 15-year follow-up period. Those
who received CHM treatments for > 180 days had a
significantly lower mortality rate than those who did not
receive CHM (P < 0.001) (Figure 1).
Table 3 presents results from an analysis that
stratified patients by age and sex. We found that females
who received CHM had a lower mortality rate than did
their non-CHM counterparts (27.10 vs 105.29 per 1000
PY, respectively), representing a covariate-adjusted
HR of 0.30 (95% CI: 0.20–0.45). The magnitude of the
association was statistically significant for male patients,
who had an adjusted HR of 0.48 (95% CI: 0.39–0.58).
Furthermore, the effect of CHM in reducing the risk of
mortality was more prominent for females aged > 50 years
(adjusted HR: 0.28; 95% CI: 0.17–0.44) (Table 3).
The most commonly prescribed CHMs for patients
with CHB and contaminant LC are summarized in Table 4.
Among these products, ten formulae were found to lessen
the subsequent risk of death, including Dan-shen, YanHu-Suo, Bei-mu, Huang-Qin, Bie-Chia, Jia-Wei-XiaoYao-San, Xiao-Chai-Hu-Tang, Shu-Jing-Huo-Xue-Tang,
Chai-Hu-Shu-Gan-Tang, and Long-Dan-Xie-Gan-Tang.

Ascites, hepatic encephalopathy, and esophageal
variceal bleeding are the 3 major complications of
cirrhosis. The presence of these complications is a sign
of decompensated liver cirrhosis and usually indicates a
poor prognosis. In Taiwan, the most common etiology
of liver cirrhosis is chronic hepatitis B (CHB) [1, 2], and
most hepatitis B virus (HBV) infections occur following
vertical transmission. In recent decades, despite the
improvement of antiviral therapy, the burden of viral
hepatitis has remained considerable. For example,
Stanaway and colleagues indicated that the number of
deaths worldwide attributable to viral hepatitis increased
from 0.89 million deaths, in 1990, to 1.45 million deaths
in 2013, an increase of 63% [3], suggesting that HBV
places a tremendous burden on patients, their families, and
the healthcare system.
Chinese herbal medicine (CHM) is the most
commonly used alternative medicine for patients with
chronic diseases, and several investigators suggested
that this approach could improve clinical outcomes or
quality of life. A recent 15-year cohort study of 112,458
patients with vertigo showed that those receiving CHM
had a significantly lower risk (36%) of stroke than did
those who did not receive CHM [4]. Another randomized
controlled trial conducted among 352 individuals with
chronic obstructive pulmonary disease compared the
effectiveness of combining conventional Western medicine
and several Chinese herbal products for 1 year [5], and
reported that integrating CHM and Western medicine
significantly improved pulmonary function, quality of
life, and psychological health (mood and depression).
Additionally, in a prior study, we found that the use of
CHM was associated with a significantly reduced risk of
hepatocellular carcinoma (HCC) in patients with CHB
[6]. These findings indicated that the integration of CHM
into allopathic clinical practice is likely to contribute to
favorable outcomes.
We conducted a comprehensive literature review
and discovered that no studies have been reported that
identified the effect of CHM on the risk of mortality for
CHB patients with concurrent liver cirrhosis (LC). Given
that the liver disease is widespread in Taiwan, to prevent
the corresponding damages, the investigation of the longterm effect of alternative treatments, specifically CHM,
for the affected patients is important. More specifically,
this study aimed to identify the effect of CHM on the
risk of morality among CHB patients using a nationwide
population-based database.

DISCUSSION
Hepatic encephalopathy, ascites, and esophageal
variceal bleeding are 3 major cirrhosis-related
complications. In clinical practice, the presence of any
of these complications is associated with decompensated
LC and is commonly predictive of a poor prognosis,
such as death [3]. Therefore, identifying alternative
treatments that can delay the progression of liver
disease is important in the prevention of deaths among
CHB patients with LC. In this study, we employed a
nationwide population-based database to investigate
the effect of CHM on the morality risk among these
patients. To increase the diagnostic accuracy for patients
who were diagnosed with CHB together with LC, all
patients in our study were identified based on ICD-9-

RESULTS
We identified 1522 patients with CHB and
contaminant LC between 1998 and 2007. Of these, 508
received CHM and 1014 were non-CHM users. Table 1
www.oncotarget.com
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Table 1: Demographic data and comorbidity comparisons
Variables

CHM nonusers

CHM users

(n = 1014)

(n = 508)

Age, (years)

P
0.003

≤ 50

461 (45.5)

255 (50.2)

 50

553 (54.5)

253 (49.8)

51.3 (11.1)

49.6 (11.2)

Mean (Standard
Deviation)
Sex

0.001

Female

251 (24.8)

166 (32.7)

Male

763 (75.2)

342 (67.3)

Monthly income

0.27

Low

382 (37.7)

182 (35.8)

Median

563 (55.5)

280 (55.1)

69 (6.8)

46 (9.1)

High
Residential area

0.93

Urban

560 (55.2)

277 (54.5)

Suburban

166 (16.4)

82 (16.1)

Rural

288 (28.4)

149 (29.3)

CCI

< 0.001

Mean (SD)

19.73 (19.2)

15.30 (16.2)

Table 2: Crude and adjusted HR of HCC for CHB patients with and without CHM usage
Patient group

Event

PY

Incidence

Crude HR(95% CI)

Adjusted HR*(95% CI)

CHM nonusers

493

3997.98

123.31

1

1

CHM users

156

3644.58

42.80

0.35 (0.33–0.46)

0.44 (0.36–0.52)

 CHM use within 30–180
days

94

1623.47

57.90

0.47 (0.41–0.64)

0.56 (0.45–0.70)

 CHM use lasted for >
180 days

62

2021.11

30.68

0.25 (0.21–0.35)

0.33 (0.25–0.42)

Incidence rate is per 1000 PY.
*
Model adjusted for age, sex, urbanization level, monthly income, and CCI scores.
CM codes and if they applied for catastrophic illness
certificate (CIC) card due to decompensated LC. This
approach robustly increases the diagnostic accuracy of
cirrhotic patients.
The effects of antiviral treatment for patients with
CHB are well established [7, 8]. In this study, we further
discovered that using CHM therapy during the standard
antiviral treatment of CHB-related decompensated LC
can lower the risk of mortality by 56%, which revealed
the positive association of CHM and lowered risk of
death among decompensated cirrhotic patients. Current
www.oncotarget.com

medical guidelines have, in the past, been unsupportive
of using CHM for CHB-related decompensated cirrhotic
patients. However, over the past decade, certain CHM
products have been commonly used for treating various
illnesses [4–6]. A previous study conducted in Taiwan
reported that the overall prevalence of insurance-covered
traditional Chinese medicine (TCM) use in patients with
liver cancer was as high as 21% [9]. In our previous
study, we found that CHM users had a significantly
lower HCC risk (37%) compared with non-CHM
users [6]. LC involves a loss of normal liver structure
18216

Oncotarget

Table 3: Age- and sex-specific incidence and adjusted HR of death in relation to CHM among CHB patients
with LCC
Variables

CHM nonusers
Case

PY

≤ 50

24

475.39

50.48

 50

82

531.34

All

106

≤ 50

CHM users  

Incidence Case

Crude HR (95% CI) Adjusted HR (95% CI)

PY

Incidence

8

647.20

12.36

0.26 (0.12–0.58)

0.41* (0.17–0.75)

154.33

26

607.35

42.81

0.28 (0.18–0.45)

0.28* (0.17–0.44)

1006.73

105.29

34

1254.55

27.10

0.26 (0.18–0.41)

0.30ƪ (0.20–0.45)

165

1598.62

103.21

57

1378.04

41.36

0.40 (0.34–0.63)

0.48* (0.35–0.61)

> 50

222

1392.63

159.41

65

1011.99

64.22

0.38 (0.35–0.59)

0.47* (0.35–0.60)

All

387

2991.25

129.38

122

2390.03

51.04

0.39 (0.36–0.55)

0.48ƪ (0.39–0.58)

Female

Male

Incidence rate is per 1000 PY.
*
Model adjusted for urbanization level, monthly income, and CCI scores.
ƪ
Model adjusted for age, urbanization level, monthly income, and CCI scores.
that interrupts the normal blood flow in the liver and
progresses to the nodules of the liver, thus resulting in
functional failure [10]. We inferred that the possible
pharmacologic mechanisms by which CHM treatment
acts on CHB patients with LC includes antiviral effects
[11], potent antioxidant activity, inhibition of free-

radical–induced hepatic fibrosis by reducing cytochrome
C [12], decreasing HBx-associated pathways [13], and
modifying the microenvironment of HCC [14]. These
effects of CHM treatments may contribute to the
alleviation of liver fibrosis and cirrhosis.

Figure 1: Survival rate according to TCM use status, all-cause mortality. P is based on the log-rank test across 3 groups.
www.oncotarget.com
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Table 4: Risk of death in relation to the top 10 used single herb and multi herb products for CHB patients with
contaminant LC
Chinese herbal
name

Scientific
name

Frequency of
prescriptions

Average
duration (day)

Daily dose (g)

Crude HR
(95% CI)

Adjusted HR*
(95% CI)

Salvia
miltiorrhiza
Bunge.,
Rhizoma

19786

9.3

10.59

0.36(0.31-0.42) 0.34(0.29-0.40)

Yan-Hu-Suo

Corydalis
yanhusuo W.T.
Wang, Rhizoma

5915

9.2

10.62

0.28(0.20-0.39) 0.29(0.21-0.42)

Hai-Piao-Xiao

Endoconcha
Sepiae,
Cuttlefish Bone

3848

7.03

9.11

0.42(0.27-1.03) 0.46(0.30-1.05)

Bei-mu

Fritillaria
thunbergii Miq.,
Balbus

3707

11.21

8.98

0.21(0.13-0.34) 0.22(0.13-0.35)

Huang-qi

Astragalus
membranaceus
(Fisch.) Bunge,
Rhizoma

3616

13.42

17.73

0.40(0.12-1.09) 0.42(0.13-1.06)

Curcuma
aromatica
Salisb.,
Rhizoma

2959

7.69

7.42

0.38(0.04-1.02) 0.37(0.03-1.01)

Hedyotis
diffusissima
Merr., Herba

3384

12.00

16.10

0.49(0.19-1.22) 0.48(0.18-1.25)

Pueraria lobata
(Willd.) Ohwi,
rhizoma

3412

8.35

9.76

0.42(0.11-1.20) 0.41(0.09-1.27)

Scutellaria
baicalensis
Georgi,
Rhizoma

3374

7.47

8.80

0.19(0.12-0.30) 0.20(0.12-0.29)

Pelodiscus
sinensis, softshelled turtle

2511

10.51

15.88

0.17(0.11-0.26) 0.18(0.12-0.27)

Jia-wei-XiaoYao-San

6064

10.43

16.93

0.25(0.19-0.36) 0.26(0.18-0.36)

Xiao-Chai-HuTang

4161

9.66

14.80

0.27(0.18-0.41) 0.27(0.19-0.40)

Shu-Jing-HuoXue-Tang

5297

7.47

11.92

0.22(0.15-0.33) 0.21(0.14-0.32)

Single-herb
products
Dan-shen

Yu-Jin

Bai-Hua-SheShe-Cao
Ge-gen

Huang-Qin

Bie-Chia
Multi-herb
products

(Continued)
www.oncotarget.com
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Chinese herbal
name

Scientific
name

Frequency of
prescriptions

Average
duration (day)

Daily dose (g)

Crude HR
(95% CI)

Adjusted HR*
(95% CI)

Chai-Hu-ShuGan-Tang

3309

10.38

21.53

0.20(0.13-0.34) 0.22(0.13-0.35)

Ping-Wei-San

4803

8.22

16.85

0.50(0.30-1.45) 0.49(0.33-1.41)

Long-Dan-XieGan-Tang

2864

8.25

15.01

0.31(0.21-0.48) 0.35(0.23-0.53)

Shao-Yao-GanCao-Tang

3952

7.09

16.04

0.39(0.10-1.08) 0.41(0.13-1.12)

Xiang-Sha-LiuJun-Zi-Tang

3935

7.47

10.68

0.42(0.14-1.34) 0.46(0.15-1.36)

Yin-Chen-WuLing-San

2603

6.88

11.26

0.36(0.10-1.01) 0.39(0.11-1.09)

Xue-Fu-ZhuYu-Tang

2697

7.44

11.55

0.34(0.08-1.11) 0.36(0.09-1.18)

Model adjusted for age, gender, urbanization level, monthly income, and CCI scores.

*

In addition, results from our study indicate that
elderly patients benefited the most from CHM in terms
of reduced risk of death. No previous studies have been
conducted to determine the long-term effect of CHM on
the risk of death among CHB patients with contaminant
LC, which precludes a comparison of results. Yet,
several possible explanations may clarify these observed
differences: First, the number of younger patients in our
study was smaller, and the rates at which they developed
adverse outcomes were somewhat lower than those of the
older patients. Second, according to a previous study of
the natural history of patients with CHB in Taiwan, the
reported risk of LC in patients with CHB begins to rise
during the patients’ 40s and increases significantly after
age 50 [15]. Additionally, during 2000-2015, the death
rates associated with LC in the US population increased
21% for men and 57% for women among persons aged
45–64 years [16]. Thus, the probability that LC risk
increases with advanced age may explain the significant
effect of CHM among elderly patients.
The present study has also listed the most commonly
prescribed single herb and multi herb products in treating
CHB patients with contaminant LC. Among the commonly
prescribed multi-herb products, we noted that Jia-weiXiao-Yao-San (JWXYS) plays a role in lowering the risk
of death. It could be argued that JWXYS which exhibits
potent antioxidant activity and inhibits free-radicalinduced hepatic fibrosis by cytochrome C reduction
[12], also contributes to better prognosis for liver cancer
patients. Chai-Hu-Shu-Gan-Tang (CHSGT) was also
found to be significantly related to lower risk of death.
We speculate that this herb could soothe the liver and
disperse the stagnated liver Qi. It should be noted that the
positive therapeutic effects derived from the components
www.oncotarget.com

of CHSGT, such as Chai-Hu, Shao-Yao, Gan-Cao and
Chuan-Xiong), were found to be identical to those of
Si-Ni-San (SNS). Our previous study showed that SNS
suppresses the HBx-induced invasiveness and metastatic
potential of hepatocellular carcinoma cells [13]. This
finding also suggests that CHSGT may reduce subsequent
risk of death among the affected patients.
Another herbal formula that possesses liver
protection, Xiao-Chai-Hu-Tang (XCHT), has been
widely used in Asian to treat chronic viral liver diseases
[6, 17, 18]. Chai-Hu (Bupleurum chinense) and Huangqin (Scutellaria baicalensis) are two of the ingredients
of XCHT. Saikosaponin-A is extracted from bupleurum,
which acts as an antioxidant and suppresses inflammation
and fibrogenesis [19]. Furthermore, several reports
demonstrated that Scutellaria baicalensis and baicalein
have anti-fibrotic effects on rat liver [20–22]. The
beneficial effect of Long-Dan-Xie-Gan-Tang (LDXGT) in
lowering risk of death was also found in the present study.
This herbal product has been proven to decrease the serum
lactate dehydrogenase (LDH) and ALT levels following
liver injury and further reduce the cell degeneration and
liver necrosis induced by CCl4, which in turn improves
the biotransformation function of the liver [23]. A further
finding indicated that Shu-Jing-Huo-Xue-Tang (SJHXT)
was related to lower risk of death. The likely explanation
for this finding is that SJHXT may have lessened the
deterioration of hepatic injury by improving blood
circulation and reducing the blood stasis syndrome [24].
Additionally, we also observed that those who used
Yan-hu-suo were at a lower risk of death. This product is a
well-known traditional CHM that was used for those with
hepatitis or liver cirrhosis and acts to strengthen the immune
system and to attenuate the pain sensory due to qi stagnation
18219
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[25]. Another commonly used single drug prescription, Bei
Mu, has been integrated into some Chinese herb formulae
for treating cancer patients. The alkaloid verticinone,
derived from Bei Mu, could exert an antinociceptive and
anti-inflammatory effects on cancer-related neuropathic
pain through both peripheral and central actions [26], which
may enhance hepatoprotective activity.
Despite the clinical and research implications
suggested by the present study, there are several
limitations to consider. First, although the severity of
LC was commonly based on the Child–Pugh score,
it was difficult to identify the laboratory data or viral
load in this database. Second, we identified patients
with CHB and liver cirrhosis using ICD-9-CM codes,
and misclassification may be possible. To decrease
the possibility of this error, we selected patients with
CHB only after they were recorded as having at least 3
outpatient visits that reported consistent diagnoses, or
at least one inpatient admission. Otherwise, all patients
with decompensated LC received a CIC from the National
Health Insurance (NHI) program in Taiwan. For these
patients, the diagnosis of decompensated LC was doublechecked, which made the diagnosis of LC in this study

more reliable. Third, during this study period, highpotency antiviral treatments for CHB such as entecavir or
tenofovir were not widely used in Taiwan. However, this is
the first nationwide population-based study that identifies
the effect of CHM on the mortality rates of patients with
CHB-related decompensated LC. Further study may be
needed to more carefully evaluate the effects of CHM for
patients with CHB-related cirrhosis, in particular if they
also concurrently receive high-potency drugs. Fourth,
evidence derived from any observational cohort study is
generally less robust than data obtained from randomized
trials because cohort study designs are subject to various
biases, including confounding effects. Further research
focusing on possible confounders identified in the
literature are warranted to fully clarify the impact of CHM
on the psychosocial health, especially on the patient’s
quality of life.
In conclusion, the use of CHM was associated
with a significantly improved survival rate among CHBrelated decompensated LC patients. The results of our
study provide strong evidence for health care providers to
consider the use of CHM therapy to improve the survive
of patients with CHB-related decompensated LC.

Figure 2: Flowchart of selection and follow-up of study subjects.
www.oncotarget.com
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MATERIALS AND METHODS

reasons other than LC. Additionally, patients who died or
were followed for < 3 months after the first CHB diagnosis
were excluded (n = 237). The outcome of interest, allcause mortality, was derived from CIC because an item
within this record notes the death date if the patient has
died. Finally, a total of 1522 subjects were included in the
data analysis.
In Taiwan, only certified Chinese medicine
physicians are entitled to provide CHM therapy. We
used the frequency of visits for TCM to verify the CHM
exposure of each study subject. Patients who received
CHM treatment for > 30 days were considered CHM
users, whereas those who were treated for ≤ 30 days
were considered non-CHM users [[4 6]]. The index date
of the follow-up period for those who were classified as
non-CHM users was assigned to begin on the date of the
first CHB diagnosis, and the index date for the followup period for CHB cases with CHM use was assigned as
the date of the initiation of CHM services. All patients
were followed from the index date to the date of death,
withdrawal from the insurance program, or the end of
2012, whichever came first.

Data source
The NHI program of Taiwan was launched in
1995 and offers coverage to approximately 99% of the
nation’s population of 25 million [27]. For research and
administrative purposes, the Taiwanese National Health
Research Institute used these claims data to establish
various database sets for public use. This retrospective
cohort study used the Longitudinal Health Insurance
Database (LHID) that comprises claims data for 1 million
beneficiaries randomly sampled from the registry for
beneficiaries of the National Health Insurance Research
Database. Because a multistage stratified systematic
sampling method was used, no statistically significant
differences were observed in age, sex, or average salary
between the sample group and all enrollees in the NHI
program [27]. This dataset contains information about all
medical services, such as ambulatory care claims, inpatient
claims, prescription drugs, and claimed medical expenses.
To date, > 300 published scientific papers have been based
on this database [28].
This study was conducted in accordance with
the Helsinki Declaration, and it was also evaluated and
approved by the local Institutional Review Board and
Ethics Committee of Buddhist Dalin Tzu Chi Hospital,
Taiwan (No. B10004021-1). Because the LHID files
contain only de-identified secondary data, the review
board waived the requirement for obtaining informed
consent from the patients.

Demographic characteristics and comorbidities
Demographic characteristics evaluated in this
study included age, sex, income for estimating insurance
payments, and urbanization level of patients’ residential
areas. Patients’ monthly incomes were stratified into 3
levels: ≤ New Taiwan Dollar (NTD) 17,880, NTD 17,881–
NTD 43,900, and ≥ NTD 43,901. Urbanization levels were
divided into 3 strata by population: urban (levels 1–2),
suburban (levels 3–4), and rural (levels 5–7) areas. Level
1 refers to the “most urbanized,” and level 7 refers to the
“least urbanized” communities [29]. We also employed the
Charlson–Deyo comorbidity index [30] to control for the
overall disease burden of various comorbidities based on
each study participant's medical records 1 year prior to
cohort entry.

Study population
The participant selection process is shown in Figure
2. All diagnoses in this insurance claims dataset were
coded using the International Classification of Disease,
9th Revision, Clinical Modification (ICD-9-CM). With it,
we identified patients 20–to-70 years of age with newly
diagnosed CHB during 1998–2007 (ICD-9-CM codes:
070.2, 070.3, or V02.61) and treatment with nucleos(t)ide
analogues (lamivudine, adefovir, telbivudine, entecavir, or
tenofovir) as the study cohort. For an accurate diagnosis of
CHB, the patients who received at least 3 diagnoses during
outpatient visits or who were admitted to a hospital with a
primary diagnosis of CHB within the observational period
were selected. The index event was defined as the first
attack of CHB. Thereafter, among all subjects we enrolled
only those who applied for a CIC due to the accompanying
LC. In Taiwan, insured residents with major diseases (eg,
cancer, chronic mental illness, end-stage renal disease,
several autoimmune diseases) can apply for the CIC card
and are not required to make copayments when seeking
healthcare for catastrophic illness. Initially, 2181 CHB
patients with the CIC card were recruited. However, 422
cases were excluded because they applied for CIC for
www.oncotarget.com

Statistical analysis
The characteristics of the cohort at baseline were
compared by t-tests and χ2 tests. The incidence rate of
mortality between 2 groups is the number of cases per
1000 person–years. Hazard ratios and 95% confidence
intervals (CI) were derived from Cox proportional hazards
regression and met the assumption of proportionality
of risks. To adjust for potential confounding in the
relationship between the baseline characteristics and
the risk of mortality, we further applied multivariate
analysis, using Cox regression to rule out the actual effect
of CHM on the risk of all-cause mortality. In addition,
to test the robustness of the relation between CHM use
and the subsequent risk of death, we divided CHM users
into 2 subgroups: 1 group used CHM for 30–180 days,
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and the other group used CHM for > 180 days. Kaplan–
Meier survival curves were generated for overall survival
probability according to 2 subtypes with respect to CHM
use. The Wilcoxon log-rank test was used to examine
for differences. Furthermore, if an interaction of age and
sex occurred with respect to the risk of death, a stratified
analysis by 2 factors was conducted to more accurately
determine the relative risk of mortality between CHM
users and non-CHM users. All statistical analyses were
conducted using SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA). A P value of < 0.05 was considered to
be statistically significant.
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